GenSight Biologics
CompanyFranceFounded 2012
GenSight Biologics develops 4 assets, the furthest in phase 1 (GS030 in retinitis pigmentosa). Mostly gene therapy and device acting on oxidative phosphorylation and MT-ND4; based in France, founded in 2012.
- 4
- Assets
- Furthest stage
- Phase 1
- Raised
- €1m
- 1
- Trial
- 3
- Signals
Pipeline
4Optogenetic gene therapy encoding a channelrhodopsin to restore light sensitivity in retinal ganglion cells
Phase 1, Gene therapy, retinitis pigmentosa
Delivers a light-sensitive opsin to retinal ganglion cells, enabling responses to light stimulation.
Phase 1, Gene therapy, non-syndromic retinitis pigmentosa
Stimulating glasses deliver light patterns to activate retinal cells sensitized by GS030-DP gene therapy.
Phase 1, Device, non-syndromic retinitis pigmentosa
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Funding rounds and grants1
- Signals3
- Similar companies6